Eleonora Gariazzo

机构：Harvard University, University of Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria, Dana-Farber Cancer Institute, Misericordia University · ORCID：0009-0002-1665-3367

发表论文 63 篇 · 总被引 95 次 · h-index 6

代表论文

• Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer (2026 · ImmunoTargets and Therapy · 被引 4)
• Clinicogenomic determinants of early progression on first-line osimertinib in EGFR -mutant NSCLC. (2026 · Journal of Clinical Oncology · 被引 1)
• Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study (2026 · Journal of Clinical Medicine · 被引 1)
• Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report (2026 · Journal of Thoracic Oncology)
• EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the ‘Rebiopsy on osi’ Study) (2026 · The Oncologist)
• PP01.48: Therapeutic Strategies and Immunotherapy Rechallenge Sensitivity After Progression Following Chemoradiation and Consolidation Durvalumab in Unresectable Stage III NSCLC: The POST-PACIFIC Study (2026 · Journal of Thoracic Oncology)